From: Possible role of HPV/EBV coinfection in anoikis resistance and development in prostate cancer
Cancer characteristic | E2 | E6 | E7 | LMP-1 | LMP-2 | EBER 1 | EBER 2 | |
---|---|---|---|---|---|---|---|---|
Types of Cancer | Acinar adenocarcinoma | 2.5 ± 2.5 | 13.1 ± 6.2 | 12.89 ± 6.3 | 14.2 ± 7.4 | 12.3 ± 11.3 | 17.8 ± 15.3 | 16.2 ± 10.2 |
Ductal adenocarcinoma | 2.4 ± 2.8 | 12.91 ± 5.9 | 13.87 ± 4.63 | 13.07 ± 11.4 | 9.7 ± 10.8 | 8.6 ± 10.1 | 8.7 ± 9.5 | |
Squamous cell cancer | 0 | 17.33 ± 4.7 | 19.17 ± 4.3 | 11.8 ± 2.7 | 13.5 ± 11.1 | 18.6 ± 7.5 | 17.2 ± 8.1 | |
P | Ns | ns | ns | Ns | ns | ns | ns | |
Stages of Cancer | I | 0 | 0 | 0 | 14.5 ± 9.2 | 17.5 ± 12.1 | 20.1 ± 11.5 | 19.8 ± 10.8 |
IIA | 0 | 13 ± 2.8 | 14 ± 4.2 | 15 ± 9.50 | 17.4 ± 9.6 | 20.3 ± 8.2 | 22.4 ± 9.7 | |
IIB | 3 ± 1.85 | 6.6 ± 2.7 | 7.3 ± 1.5 | 10.8 ± 5.33 | 7.6 ± 12.6 | 9.8 ± 16.3 | 8.21 ± 4.04 | |
IIC | 0 | 0 | 0 | 12.8 ± 6.9 | 12.8 ± 11.9 | 17.3 ± 7.2 | 15 ± 5.11 | |
IIIA | 0 | 0 | 0 | 8 ± 6.31 | 11 ± 3.2 | 9.8 ± 11.2 | 12.3 ± 10.4 | |
IIIB | 4.5 ± 1.99 | 13.8 ± 4.9 | 11.6 ± 4.8 | 7.5 ± 10.2 | 7.9 ± 7.3 | 16.8 ± 5.9 | 11.3 ± 4.8 | |
IIIC | 3 ± 0.54 | 14.5 ± 7.5 | 17 ± 1.8 | 9.8 ± 9.01 | 7.1 ± 8.3 | 8.9 ± 9.02 | 10.8 ± 3.3 | |
IVA | 5.4 ± 2.8 | 12.7 ± 4.3 | 13.4 ± 3.9 | 12 ± 11.7 | 15.1 ± 11.8 | 11.5 ± 7.2 | 12.6 ± 4.52 | |
IVB | 0 | 15.5 ± 2.7 | 17.2 ± 2.5 | 15 ± 11.9 | 16.5 ± 11.2 | 17.2 ± 7.7 | 13.7 ± 6.2 | |
P | Ns | ns | ns | ns | ns | ns | ns |